enGene Therapeutics Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
enGene Therapeutics Inc. (ENGN) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $7.81 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-09-08
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-07-31 was $7.81M, a 202.60% increase year-over-year.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-04-30 was $4.14M, a 56.42% increase year-over-year.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-01-31 was $2.80M, a 54.95% increase year-over-year.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-07-31 was $2.58M, a 76.78% increase year-over-year.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $9.65M, a 81.18% increase from fiscal 2024.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $5.32M, a 54.32% increase from fiscal 2023.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $3.45M, a 2874.14% increase from fiscal 2022.
- enGene Therapeutics Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $116.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-07-31 | $7.81M 10-Q · filed 2026-09-08 | $11.96M derived: sum of 2 quarters · filed 2026-09-08 | $14.76M derived: sum of 3 quarters · filed 2026-09-08 | |
| 2026-04-30 | $4.14M 10-Q · filed 2026-09-08 | $6.95M derived: sum of 2 quarters · filed 2026-09-08 | ||
| 2026-01-31 | $2.80M 10-Q · filed 2026-09-08 | |||
| 2025-10-31 | $9.65M 10-K · filed 2025-12-22 | |||
| 2025-07-31 | $2.58M 10-Q · filed 2026-09-08 | $5.23M derived: sum of 2 quarters · filed 2026-09-08 | $7.04M derived: sum of 3 quarters · filed 2026-09-08 | |
| 2025-04-30 | $2.65M 10-Q · filed 2026-09-08 | $4.46M derived: sum of 2 quarters · filed 2026-09-08 | ||
| 2025-01-31 | $1.81M 10-Q · filed 2026-09-08 | |||
| 2024-10-31 | $5.32M 10-K · filed 2025-12-22 | |||
| 2024-07-31 | $1.46M 10-Q · filed 2025-09-11 | $3.38M derived: sum of 2 quarters · filed 2025-09-11 | $3.67M derived: sum of 3 quarters · filed 2025-09-11 | |
| 2024-04-30 | $1.92M 10-Q · filed 2025-09-11 | $2.21M derived: sum of 2 quarters · filed 2025-09-11 | ||
| 2024-01-31 | $291.00K 10-Q · filed 2025-09-11 | |||
| 2023-10-31 | $3.45M 10-K · filed 2024-12-19 | |||
| 2023-07-31 | $37.00K 10-Q · filed 2024-09-10 | $76.00K derived: sum of 2 quarters · filed 2024-09-10 | $96.00K derived: sum of 3 quarters · filed 2024-09-10 | |
| 2023-04-30 | $39.00K 10-Q · filed 2024-09-10 | $59.00K derived: sum of 2 quarters · filed 2024-09-10 | ||
| 2023-01-31 | $20.00K 10-Q · filed 2024-09-10 | |||
| 2022-10-31 | $116.00K 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |